Influenza drug Avigan or Favipiravir has been effective in helping coronavirus patients recover, with almost no side-effects, China's ministry of science and technology said earlier this week.
Better known for its cameras, Fujifilm developed Avigan (name of the drug) and licensed the patent for favipiravir to Chinese company Zhejiang Hisun Pharmaceutical.
An official at China’s Science and Technology Ministry, Zhang Xinmin, said on Tuesday that some clinical trials have been completed on favipiravir -- the main ingredient in the influenza drug Avigan, which Fujifilm markets.
The trials using the drug as a treatment for COVID-19 showed "very good clinical results", the official said at a press conference.
Read more: China reports zero new domestic cases of novel coronavirus for first time in months
A trial involving 80 cases conducted by a hospital in Shenzhen and a study of 120 cases led by Wuhan University's Zhongnan Hospital both showed the drug shortened the recovery time for patients.
Clinical tests using Avigan as a treatment for the virus have also started in Japan.
Shares in Japanese firm Fujifilm Holdings sky-rocketed on Wednesday after the drug got an endorsement from the Chinese authorities.
Fujifilm Holdings stock started the day untraded because of a glut of buy orders, before soaring 15.4 percent to 5,238 yen, the highest level allowed during trade for the day.
Senior US official underscores increasing concern within Pentagon over action against civilian employees
Delegates hope to resolve summit's top agenda for developing countries
Those responsible for indiscriminate killings will be brought back from wherever they have taken refuge, says official
Iran has always denied having ambitions to develop nuclear weapon
Cairo’s historic cemetery witnesses demolition and displacing families, altering city’s heritage
US Fed has dual mandate from Congress to act independently to tackle both inflation and unemployment
